Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Cash (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Change in Cash data on record, last reported at -$11.8 million in Q3 2025.

  • For Q3 2025, Change in Cash fell 16.37% year-over-year to -$11.8 million; the TTM value through Sep 2025 reached -$1.8 million, up 88.25%, while the annual FY2024 figure was -$3.9 million, 619.85% down from the prior year.
  • Change in Cash reached -$11.8 million in Q3 2025 per CRVS's latest filing, down from $9.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $12.4 million in Q3 2023 and bottomed at -$32.0 million in Q1 2022.
  • Average Change in Cash over 4 years is -$4.0 million, with a median of -$3.7 million recorded in 2025.
  • The widest YoY moves for Change in Cash: up 469.99% in 2024, down 181.63% in 2024.
  • A 4-year view of Change in Cash shows it stood at -$11.4 million in 2022, then skyrocketed by 34.51% to -$7.5 million in 2023, then skyrocketed by 154.24% to $4.1 million in 2024, then crashed by 391.23% to -$11.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were -$11.8 million in Q3 2025, $9.7 million in Q2 2025, and -$3.7 million in Q1 2025.